CYPATCH - the cell delivery coating
Diabetes is the fastest growing chronic disease worldwide, affecting an estimated 425 million adults (1 in 11) globally in 2017 and forecasted to affect 629 million adults by 2045.
Up to 34% of those with diabetes will develop a foot ulcer, providing a portal for infection that can lead to life-threatening sepsis and/or amputation. With one diabetes-related extremity amputation now performed every 20 seconds, the burden on society associated with this condition is extremely.
Independent studies, utilising TekCyte’s coated dressing, were conducted by the Cooperative Research Centre for Cell Therapy Manufacturing (CTM-CRC), designed to compare Cynata’s Cymerus® cells with similar cells from various sources. The results showed that Cymerus cells were one of the most effective at accelerating wound repair in a small animal model.
Having secured a world-wide exclusive license from TekCyte, Cynata now plans to conduct a human clinical trial in patients with diabetic foot ulcers.
Ann: Successful Completion of Planned DSMB Review of DFU Trial, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.015(9.68%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 15.5¢ | 17.0¢ | 15.5¢ | $47.10K | 289.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.0¢ | 23813 | 3 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |